Corvus Pharmaceuticals, Inc. (CRVS) Reports In-Line Q1 EPS

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q1 EPS of ($0.12), in-line with the analyst estimate of ($0.12).

For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Prosperity Bancshares (PB) Reiterated at Overweight by Cantor Fitzgerald as Estimates Revised